Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma

Trial Profile

Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 26 Jan 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Rituximab; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms ENRICH
  • Most Recent Events

    • 26 Jan 2017 New source identified and integrated. (EudraCT2015-000832-13; European Clinical Trials Database).
    • 24 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ISRCTN: Current Controlled Trials record.
    • 14 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top